H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Lisata Therapeutics today and set a price target of $15.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Joseph Pantginis has given his Buy rating due to a combination of factors surrounding Lisata Therapeutics’ recent financial performance and the progress of its lead candidate, certepetide. The company reported better-than-expected earnings per share for the second quarter of 2025, and it maintains a solid cash position that is projected to support ongoing and planned trials through the fourth quarter of 2026.
Furthermore, Lisata is making significant strides with its certepetide programs across multiple indications. The company is preparing for a Phase 3 trial for its ASCEND study in metastatic pancreatic ductal adenocarcinoma, having reached an agreement with the FDA on key trial elements. Additionally, the BOLSTER trial in cholangiocarcinoma is progressing ahead of schedule, and other studies, such as CENDIFOX and the glioblastoma multiforme trial, are advancing steadily. These developments suggest a promising outlook for Lisata’s pipeline, supporting the Buy rating.
Pantginis covers the Healthcare sector, focusing on stocks such as Capricor Therapeutics, Krystal Biotech, and Iovance Biotherapeutics. According to TipRanks, Pantginis has an average return of -10.0% and a 36.60% success rate on recommended stocks.